ADO and neoplasm: In the tumor context, this response is subverted, mainly by the sequential processing of exATP into ADO by action of the CD39 and CD73 ectonucleotidase pathway; ADO acts as an immunosuppressive molecule directing the phenotype of infiltrated immune cells in the TME dismantling the antitumor immune attack [24,30,131].